Results 121 to 130 of about 7,450 (200)

Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids [PDF]

open access: yes, 2017
Glucosylceramide synthase (GCS) catalyzes the first committed step in the biosynthesis of glucosylceramide (GlcCer)-related glycosphingolipids (GSLs). Although inhibitors of GCS, PPMP and PDMP have been widely used to elucidate their biological function ...
Alam, Shahidul   +3 more
core  

Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model

open access: yesCancers
Simple Summary Neuroblastoma (NB), a prevalent childhood cancer, presents challenges in treatment due to its cellular diversity and the presence of tumor-derived endothelial cells (TECs) associated with chemoresistance.
Aranzazu Villasante   +6 more
semanticscholar   +1 more source

Impaired plasma membrane calcium ATPase activity and mitochondrial dysfunction contribute to calcium dysregulation in Fabry disease-related painful neuropathy

open access: yesNeurobiology of Disease
Neuropathic pain is a hallmark symptom in Fabry disease (FD), a hereditary X-linked lysosomal storage disorder caused by a reduced activity of α-galactosidase A (α-Gal A).
Francesco Formaggio   +10 more
doaj   +1 more source

Gas Phase Infrared Spectroscopy of Glycolipids

open access: yes, 2019
Carbohydrates and lipids are not only energy sources and structural components of cells but fulfill very diverse and important roles in a multitude of cellular processes. The combination of a carbohydrate and a lipid linked via a glycosidic bond yields a
Kirschbaum, C.
core  

From Shoulder to Heart: Acute Shoulder Pain Leads to a Diagnosis of Fabry Disease. [PDF]

open access: yesJACC Case Rep
Kalaria A   +4 more
europepmc   +1 more source

Systemic metabolic reprogramming and microbial dysbiosis in Fabry disease: Multi-omics mechanisms and implications for drug development. [PDF]

open access: yesFront Pharmacol
Gómez-Cebrián N   +5 more
europepmc   +1 more source

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension. [PDF]

open access: yesNat Commun
Nordbeck P   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy